From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
The Power of Timing: Therapies That Change Outcomes
Precision in Practice—Bringing Targeted Therapy to mHSPC
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS
Prithviraj Bose, MD
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP
Bilal Siddiqui, MD
Applying Clinical Trial Data in mCSPC Care
Steve Jackson, PharmD
Jahan Aghalar, MD
Ulka Vaishampayan, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.